Research programme: venomics - QRxPharma

Drug Profile

Research programme: venomics - QRxPharma

Alternative Names: Haempatch; Q 70050; Q 8008; Q 8009; Q 8010; Textilinin

Latest Information Update: 07 Jul 2011

Price : $50

At a glance

  • Originator QRxPharma
  • Developer QRxPharma; The University of Queensland
  • Class Enzymes; Peptides; Venoms
  • Mechanism of Action Plasmin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Haemorrhage

Most Recent Events

  • 31 Dec 2008 Early research is ongoing in Australia
  • 03 Feb 2005 Early research in Haemorrhage in Australia (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top